Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 205 publications
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.
Journal: European urology
Published: May 11, 2026
Head-to-head Comparison of Multimodal Imaging for Prostate Cancer Detection and Local Staging with Whole-mount Histopathology Reference.
Journal: European urology oncology
Published: January 30, 2026
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 12, 2025
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.
Journal: Lancet (London, England)
Published: October 01, 2025
Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer.
Journal: International journal of radiation oncology, biology, physics
Published: August 29, 2025
Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial.
Journal: European urology oncology
Published: August 12, 2025
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.
Journal: European urology
Published: July 01, 2025
Deep Learning-based Anatomy-Aware Morph Model for Registration of Prostate Whole-Mount Histopathology to MRI.
Journal: Radiology. Imaging cancer
Published: May 30, 2025
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: May 15, 2025
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy.
Journal: European urology oncology
Published: April 16, 2025
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 15, 2025
Last Updated: 09/26/2026